Cannabis use in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials (RCTs).
The read
A follow-up to the Naftali trial covered above: this is a meta-analysis pooling randomized controlled trials of cannabis in Crohn's disease, pre-registered with PROSPERO and following PRISMA 2020 reporting standards, so the process itself is more rigorous than a typical roundup of studies.
The pooled result favors cannabis on the main disease-activity measure. Patients using cannabis had significantly lower Crohn's Disease Activity Index scores at 8 weeks than the control group, consistent with the higher remission rates individual trials like Naftali's have reported. CRP, the blood marker for active inflammation, trended lower in the cannabis group too, but the difference did not reach statistical significance, so the review cannot say cannabis measurably calmed inflammation at the biomarker level.
The counterintuitive finding is quality of life. Placebo patients reported significantly better quality-of-life scores than the cannabis group did. That is a real mismatch: the same body of trials shows cannabis improving the standard disease-activity score while patients on placebo felt better about their day-to-day life. The review does not explain why, and neither can this summary. It could be a side-effect burden that standard activity indices don't capture, a small-sample fluke, or something about how patients weigh symptom relief against side effects like fatigue or brain fog. It is worth knowing about before assuming a lower CDAI number means a better lived experience.
The evidence base here is still thin. This pools a small number of RCTs, several of them individually tiny, and the products tested (smoked flower at fixed THC doses, in most included trials) do not represent the full range of cannabis products patients actually use.
- Meta-analysis of RCTs, pre-registered with PROSPERO, PRISMA 2020 methodology: cannabis significantly outperformed placebo on Crohn's Disease Activity Index score at 8 weeks.
- CRP (inflammation marker) trended lower with cannabis but did not reach statistical significance.
- Quality-of-life scores were significantly better in the placebo group than the cannabis group, a genuine mismatch with the disease-activity result.
- Pools trials including the Naftali 2013 study covered elsewhere on this site.
- Small number of underlying RCTs, several individually tiny, limits how precise the pooled estimate really is.
- The disease-activity-improves-but-quality-of-life-doesn't-follow pattern is not explained by the review and needs more research.
- Trials mostly test smoked flower at fixed THC doses, not the edibles, tinctures, or CBD-forward products many patients actually use.
- Inflammation markers did not move significantly, so symptom control and disease modification remain separate, unresolved questions.